

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-66190
Application Number	10/607,598
Filing Date	June 27, 2003
First Named Inventor	Martin
Art Unit	1646 1647
Examiner Name	Not yet assigned J. Seharaseyon

## U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
JS		5,530,101	06/25/1996	Queen et al.
↓		5,585,089	12/17/1996	Queen et al.
		5,620,686	04/15/1997	Mason
		5,693,762	12/02/1997	Queen et al.
		6,013,256	01/11/2001	Light et al.
		6,096,728	01/08/2001	Collins et al.
		6,180,370	01/30/2001	Queen et al.
		6,346,247	02/12/2002	Stafford et al.


## FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
JS		WO 89/09622	10/19/1989	WIPO
↓		WO 90/07861	07/26/1990	WIPO
		WO 92/13886	08/20/1992	WIPO
		WO 93/01289	01/21/1993	WIPO
		WO 00/25816	05/11/2000	WIPO

EXAMINER  
SIGNATURE: /Jegatheesan Seharaseyon/

DATE  
CONSIDERED: 07/28/2006

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-66190
Application Number	10/607,598
Filing Date	June 27, 2003
First Named Inventor	Martin
Art Unit	1646 1647
Examiner Name	<del>Not yet assigned</del> J. Seharaseyon

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
JS		"Advances in Basic and Clinical Research on MS Reported at AAN," <a href="http://www.nationalmssociety.org/Research-2003Apr15.asp">www.nationalmssociety.org/Research-2003Apr15.asp</a> , April 15, 2003.
		Bellamy et al., "The distribution of interleukin-2 receptor bearing lymphocytes in multiple sclerosis: evidence for a key role of activated lymphocytes," <i>Clin. Exp. Immunol.</i> 61: 248-256, 1985.
		Brown et al., "Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival," <i>Proc. Natl. Acad. Sci. USA</i> 88: 2663-2667, 1991.
		Church, A., "Clinical advances in therapies targeting the interleukin-2 receptor," <i>Q J Med</i> 96: 91-102, 2003.
		Giorelli et al., "IFN- $\beta$ 1a Modulates the Expression of CTLA-4 and CD28 Splice Variants in Human Mononuclear Cells: Induction of Soluble Isoforms," <i>Journal of Interferon and Cytokine Research</i> 21: 809-812, 2001.
		Junghans et al., "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders," <i>Cancer Res.</i> 50(5): 1495-1502, 1990.
		Khoury et al., "Changes in Activated T Cells in the Blood Correlate with Disease Activity in Multiple Sclerosis," <i>Arch. Neurol</i> 57: 1183-1189, 2000.
		Lee et al., "Spatial mapping of T <sub>2</sub> and gadolinium-enhancing T <sub>1</sub> lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?" <i>Brain</i> 122: 1261-1270, 1999.
		Lehky et al., "Reduction in HTLV-I Proviral Load and Spontaneous Lymphoproliferation in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis Patients Treated with Humanized Anti-Tac," <i>Annals of Neurology</i> 44: 942-947, 1998.
		Marwick, C., "Scientists Recall Progress and Promise of Translational Research," <i>J. Natl. Cancer Inst.</i> 93: 13-15, 2001.
		"Monoclonal antibodies with clinical indications," <a href="http://www.imgt.cines.fr:8104/textes/IMGTrepertoire/GenesClinical/monoclonalantibodies">www.imgt.cines.fr:8104/textes/IMGTrepertoire/GenesClinical/monoclonalantibodies</a> , May 19, 2003.
		Nussenblatt et al., "Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial," <i>Proc. Natl. Acad. Sci. USA</i> 96 (13): 7462-7466, 1999.
		Package insert for Rebif (interferon beta-1a), November 6, 2002.

EXAMINER  
SIGNATURE:

/Jegatheesan Seharaseyon/

DATE

CONSIDERED: 07/28/2006

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Attorney Docket Number</b>	4239-66190
		<b>Application Number</b>	10/607,598
		<b>Filing Date</b>	June 27, 2003
		<b>First Named Inventor</b>	Martin
		<b>Art Unit</b>	1646- 1647
		<b>Examiner Name</b>	Not yet assigned J. Seharaseyon
JS		Package insert for Zenapax (Daclizumab), December 1997.	
		Paty et al., "Interferon beta-1b is effective in relapsing-remitting multiple sclerosis," <i>Neurology</i> 43:662-667	
		Posey et al., "TCP presents its annual list of drugs in development and what their approval will mean to long-term care patients," <a href="http://www.ascp.com/public/pubs/tcp/1997/apr/newdrugs.html">www.ascp.com/public/pubs/tcp/1997/apr/newdrugs.html</a> , June 4, 2002.	
		Queen et al., "A humanized antibody that binds to the interleukin 2 receptor," <i>Proc. Natl. Acad. Sci. USA</i> 86 (24): 10029-10033, 1989.	
		Samkoff, Lawrence, "Multiple Sclerosis: Update of Treatment," <i>Hospital Physician</i> pp. 21-27, 2002.	
		"Study of Zenapax in the treatment of multiple sclerosis," <a href="http://www.mult.sclerosis.org/news/Nov2000/ZenapaxMS.html">www.mult.sclerosis.org/news/Nov2000/ZenapaxMS.html</a> , November 27, 2000.	
		Waldmann, et al., "Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy," <i>Hematology</i> (1): 394, 2000.	
		Wandinger et al., "Complex Immunomodulatory Effects of Interferon-beta in Multiple Sclerosis Include the Upregulation of T Helper 1-associated Marker Genes," <i>Ann. Neurol.</i> , 50(3):349-57 (2001).	

<b>EXAMINER SIGNATURE:</b>	/Jegatheesan Seharaseyon/	<b>DATE CONSIDERED:</b>	07/28/2006
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.			

SAS:gle 07/28/04 4239-66190-01 296821

JUL 29 2004

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

<b>Attorney Docket Number</b>	<b>4239-66190-01</b>
-------------------------------	----------------------

<b>Application Number</b>	10/607,598
---------------------------	------------

<b>Filing Date</b>	June 27, 2003
--------------------	---------------

<b>First Named Inventor</b>	<b>Martin</b>
-----------------------------	---------------

Art Unit	1646-1647
----------	-----------

<b>Examiner Name</b>	<b>Not yet assigned</b>
----------------------	-------------------------

~~J. Scharaseyon~~

**Examiner's  
Initials\***

**Cite No.**  
**(optional)**

## OTHER DOCUMENTS

JS

**NUSSENBLATT *et al.*, Proc. Natl. Acad. Sci. USA, 96:7462-7466, 1999**

JS

PATTI *et al.*, *Acta Neurol. Scand.*, 100:283-289, 1999

**EXAMINER**


**SIGNATURE:** /Jegatheesan Seharaseyon/

DATE \_\_\_\_\_

**CONSIDERED:**

07/28/2006

\* **Examiner:** Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>Attorney Docket Number</b>	4239-66190-01
<b>Application Number</b>	10/607,598
<b>Filing Date</b>	June 27, 2003
<b>First Named Inventor</b>	Martin
<b>Art Unit</b>	<del>1646</del> 1647
<b>Examiner Name</b>	Jegatheesan Seharaseyon

EXAMINER SIGNATURE:	/Jegatheesan Seharaseyon/	DATE CONSIDERED:	07/28/2006
------------------------	---------------------------	---------------------	------------

Information Disclosure Statement (1449) Page 1 of 1